appears you know what the hell your talking about--appreciate that give the bs I see on most boards--I come from pharma so i don't know jack about devices other than the life cycles are more like chips than drugs.
in long on stj per a newsletter reco--where's this headed??
ps have a very good friend at GDT--he's richer than dirt off his options and 5 yrs my jr--right place, right time....they seem to be kicking ass?
Remember the Scimed days when Angioplasty was just starting,remember the performance of Scimed stock back then, well, STJ will create a new industry in the By Pass Surgery arena. With the advent of minimally invasive cardiac surgery this new product will allow most surgeons to perform this proceadure on a beating heart with high precision and in record time, STJ has the best sales force in the cardiac surgery industry, they will make this product a success,they will bring this to market in record time and capture the lions share for this type of devices. The CRMD division is full steam ahead capturing significant market share from both GDT and MDT,with the new Photon dual chamber ICD and all the CHF applications in clinicals, well, the story is just begining. STJ longs will be rewarded.
I'm in on the same newsletter reco as you, I imagine. I've done a fair amount of DD on this one and see little to no downside. It's a value play with a growth profile, significant discount to peers, solid performance several quarters running, and with even a little respect from the sell side has an easy shot at 50% ROI from here. GDT has had a great run and has definitely kicked ass in a few key segments. However look at their 10-K closely and see the cracks forming--- legal issues in particular. Also year over year performance comps are gonna be real hard from here on out. I question the multiple on this one for sure. IMHO. BTW, takes me at least a hard 7 to do 160.